Form 4: Indaptus Therapeutics Director Cancels Stock Options, Receives $500 Consideration
SEC Filing
Director William B Hayes cancels stock options in Indaptus Therapeutics, receiving $500 in consideration.
Summary
- William B Hayes, a director of Indaptus Therapeutics, filed a Form 4 indicating changes in beneficial ownership.
- On April 10, 2025, Hayes canceled stock options to buy 500 shares at $24.60, 250 shares at $388.64 and 250 shares at $355.20.
- The options were canceled by mutual agreement, and Hayes received a total of $500 as consideration for the cancellation.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing the cancellation of stock options. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions and provides limited insight into broader industry trends.
Stakeholder Impact
- The cancellation of stock options and the $500 consideration may have a minor impact on the director's personal finances.
- The cancellation of the options has a negligible impact on shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/28/2018 | Date of stock option grant for 250 shares at $355.20, expiring 06/28/2025. |
| 06/28/2019 | Date of stock option grant for 250 shares at $388.64, expiring 06/28/2026. |
| 07/15/2020 | Date of stock option grant for 500 shares at $24.60, expiring 07/15/2027. |
| 04/10/2025 | Date of transaction: Cancellation of stock options. |
| 04/11/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, stock options, Indaptus Therapeutics, beneficial ownership, director, INDP, cancellation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.